{"id":"W2166934777","doi":"10.1210/jc.2015-1520","title":"Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial","year":2015,"lang":"en","type":"article","venue":"The Journal of Clinical Endocrinology & Metabolism","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":221,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université du Québec à Chicoutimi; Université de Montréal","funders":"Amarin Corporation; Ipsen; Regeneron Pharmaceuticals; Eisai; Daiichi Sankyo Europe; Sanofi; Genentech; Bristol-Myers Squibb; AstraZeneca; Daiichi-Sankyo; Amgen; Pfizer","keywords":"Alirocumab; Atorvastatin; PCSK9; Ezetimibe; Rosuvastatin; Medicine; Pharmacology; Regimen; Internal medicine; Statin; Urology; Cholesterol; Apolipoprotein B; Lipoprotein; LDL receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00159905,0.001382532,0.002811307,0.0004104097,0.0003921444,0.001260716,0.000707432,0.001554863,0.009265579],"category_scores_gemma":[0.001922411,0.0005186452,0.002380246,0.0003760072,0.000966042,0.0009723943,0.0006455151,0.001925792,0.0006719154],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008976566,"about_ca_system_score_gemma":0.001262797,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001684048,"about_ca_topic_score_gemma":0.003142498,"domain_scores_codex":[0.9992303,0.0004368597,0.00004835589,0.0001360342,0.00004780857,0.0001007],"domain_scores_gemma":[0.9992561,0.000215063,0.0001805957,0.00005588706,0.00005019961,0.0002422376],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9826575,0.001503195,0.0004527148,0.001217581,0.001575481,0.00003090264,0.00003376319,0.0002193829,0.0006372301,0.0001993862,0.0009842991,0.01048852],"study_design_scores_gemma":[0.98619,0.01062243,0.0006818585,0.00008867683,0.00123711,0.00002017996,0.00001973587,0.0003718804,0.0001078034,0.0001811936,0.0004686841,0.00001047337],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9491104,0.02896339,0.001845673,0.003198785,0.001541348,0.005935812,0.0026446,0.0003043717,0.006455534],"genre_scores_gemma":[0.9717675,0.008200245,0.002595994,0.003517307,0.0009370861,0.005885819,0.001300107,0.00003265827,0.005763321],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009265579,"threshold_uncertainty_score":0.03099644,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1373651670151855,"score_gpt":0.4489970766668255,"score_spread":0.31163190965164,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}